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ABSTRACT
Objective The aim of this study was to investigate health professionals’ opinions toward offering noninvasive prenatal
testing (NIPT) as first-tier screening test regardless of pregnant women’s risk, and toward a potential broader range
of disorders.
Methods A questionnaire completed by obstetric health professionals (n = 240) after an in-service NIPT training in the
West and North of the Netherlands.
Results The majority (72%) of respondents favored replacing first-trimester combined test (FCT) by NIPT, although
43% preferred to maintain nuchal translucency measurement. Many respondents believed that replacing FCT by
NIPT would only have advantages (57%), would lead to more pregnant women opting for prenatal testing (69%),
and would simplify counseling (47%). Differences in attitudes toward counseling between health professionals were
observed. When considering NIPT to screen for broader range of disorders, the majority (92%) thought that this
should include disorders characterized by neonatal death, whereas 52% of the respondents favored testing for
fetomaternal risk factors. Overall, 46% thought screening should be offered as a fixed list of disorders.
Conclusion Most health professionals favor NIPT instead of FCT but prefer to maintain nuchal translucency
measurement. If NIPT becomes available as a first-tier screening test, attention remains necessary to ensure
that pregnant women make well-informed decisions in line with the aim of prenatal screening. © 2015 John Wiley
& Sons, Ltd.
Funding sources: The study was funded by the Netherlands Organization for Health Research and Development (ZonMw, grant no: 209020003) as part of the
Regional Perinatal Network Northwest Netherlands.
Conflicts of interest: The authors are employed by University Medical Centers that offer NIPT as part of their clinical genetic services.
INTRODUCTION
The introduction of noninvasive prenatal testing (NIPT) has
significantly changed the field of prenatal screening. With NIPT,
circulating cell-free fetal DNA (of placental origin) can be
detected inmaternal plasma.1 NIPT is an accurate screening test
for trisomy 21, 18, and 13 in both high-risk and low-risk
pregnancies,2,3 with a sensitivity of >99% and a false positive
rate of<0.1.4,5 These test characteristics are far superior to those
of the first-trimester combined test (FCT).6,7 Moreover, NIPT
can be performed from 10weeks of gestation onwards and
carries no miscarriage risk. In affected families, NIPT can also
be used to determine paternally inherited conditions, fetal sex
for sex-linked disorders, and single-gene disorders such as
achondroplasia.4 In commercial settings, NIPT is offered to
detect chromosomal deletions and/or duplications and fetal
sex determination for non-medical reasons.8,9 Initially, in accor-
dance with international guidelines,10,11 NIPT was introduced as
a test for women at ‘high risk’ of having a child with trisomy 21,
18, or 13. However, recently, the International Society for
Prenatal Diagnosis considered it appropriate to offer cell-free
DNA testing as a primary test to all pregnant women.12 To
exclude false positives, a positive NIPT result should always be
confirmed with amniocentesis or chorionic villus sampling,
signifying that NIPT-based testing remains a two-step
procedure.12,13 Therefore, NIPT is increasingly called cell-free
DNA (cfDNA) screening.
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An important prerequisite for responsible implementation of
NIPT is health professional support. Should NIPT be imple-
mented as a first-tier screening test, health professionals need
to be aware of the mechanisms, test characteristics, and clinical
utility of NIPT to offer accurate pretest counseling in order to
facilitate pregnant women’s informed choice. In the USA,
attitudes of health professionals toward offering NIPT as a
first-tier screening test are generally favorable.10,11 A survey
study among 222 members of the American College of
Obstetrics and Gynecology has shown that 79% believe that
NIPT should be offered as a first-tier screening test.14 Another
study among 101 US obstetricians shows similar results.15
However, offering NIPT to all pregnant women raises the
concern that NIPT is being presented and regarded as a routine
procedure. This ‘routinization’ would be at odds with the notion
that prenatal screening for fetal anomalies is offered to facilitate
autonomous reproductive decision-making.16,17 Moreover, the
trade-offs involved in prenatal testing may differ for health
professionals and pregnant women: the first tend to place most
value on the accuracy of a test, whereas pregnant women
consider safety of the test to be the most important feature.18–20
Because the entire fetal genome is represented in maternal
plasma,21,22 the scope of NIPT is expected to broaden in the
near future. Extending NIPT to screen for severe genetic
disorders is supported by health professionals.14,20,23 Screening
for phenotypically mild disorders and adult-onset disorders
received less support, possibly because of the controversy
regarding testing for conditions that causes less or no harm
and requires little to no medical care.14,20,23
If NIPT becomes available for a broader range of disorders,
discussion is needed on the implementation in prenatal care.
A focus group study in the Netherlands showed differences
between stakeholders regarding preferences on broader
prenatal testing.24 Pregnant women preferred to choose
individually from a wide range of possible test options,
whereas most health professionals opted for a test limited to
a number of severe conditions.23
In the Netherlands, all pregnant women are informed on
prenatal aneuploidy screening since 2007. More than 80% of
pregnant women receive counseling for prenatal screening
from primary care midwives.25 The overall uptake rate of FCT-
based prenatal screening for trisomy 21, 13, and 18 is around
27%,26 but regional differences do exist.27 Since April 2014, NIPT
is offered as a second-tier test after FCT as part of a national
implementation study (TRIDENT study, trial by Dutch
laboratories for Evaluation of Noninvasive prenatal Testing).28
The aim of this study was to evaluate the opinion of health
professionals regarding: (1) the position of NIPT in the prenatal
screening program, (2) the potential replacement of FCT by
NIPT and possible consequences for counseling, and (3) the
range of disorders for which NIPT should be made available
and ‘how to offer’ NIPT for a broader range of disorders.
Differences between health professionals with different
professional backgrounds were also assessed.
METHODS
A quantitative survey using a questionnaire was conducted.
Ethical approval was granted by the Medical Ethical Committee
of the VU University Medical Center (VUMC) in Amsterdam
(grant no: 2012/106).
Respondents and procedures
A survey was performed among health professionals (midwives,
gynecologists, and sonographers) working in two regions in the
Netherlands: the West (Amsterdam) and the North (Groningen)
(Table 1). Questionnaires were distributed after an in-service
training for NIPT organized by the Regional Centers for Prenatal
Screening in Amsterdam and Groningen in November 2013 and
March 2014, respectively. Thus, the questionnaires were
distributed before or right at the time NIPT was first introduced
in the Netherlands. Additionally, health professionals were
recruited from the departments of Obstetrics and Gynecology
at the two University Medical Centers in Amsterdam (VUMC
and Academic Medical Center). In Groningen, health
professionals could also fill in an online version of the survey
during the month of July 2014.
Survey instrument
The questionnaire was designed by an interdisciplinary
group consisting of an ethicist, a health scientist, a psycho-
logist and a gynecologist. The questionnaire was distributed
simultaneously with international discrete choice experiment,19
which will be published elsewhere. First, a brief description of
NIPT as a screening test for common aneuploidies, including
Table 1 Demographic characteristics of respondents
Characteristics n = 240, n (%)





Gender Female 226 (94)
Male 12 (5)
Profession Midwifea 140 (58)









Work region Amsterdam 151 (63)
Groningen 89 (37)
Totals may not add up to 100% because of missing values and rounding.
aIncluded midwives in training (n = 5).
bIncluded gynecologists in training (n = 2).
cOther professions included the following: genetic counselors (n = 2), nurses (n = 2),
administrative workers in prenatal screening (n = 2), teacher (n = 1), fertility doctor
(n = 1), and physician assistant (n = 1).
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test characteristics, was given. The opinion of health pro-
fessionals on the position of NIPT in the prenatal screening
program was assessed (5 answers; Figure 1).
Specific questions assessed the attitudes of respondents
toward replacement of FCT by NIPT and the possible
consequences for counseling (9 statements; Table 2). A 5-point
Likert scale was used to categorize respondents’ answers
(1 = completely disagree to 5 = completely agree).
Health professionals were asked to rank information about
NIPT in order of importance to pregnant women (6 options,
1 =most important to 6 = least important; Figure 2).
Two questions concerned NIPT screening for a broader
range of disorders, based on the study by Van Schendel
et al.,29 assessing pregnant women’s attitudes toward NIPT-
based screening (and beyond). The first question evaluated
the preferred scope of NIPT. The second question examined
how to offer NIPT when screening for a broader range of
disorders. Three options were listed: (1) ‘closed offer’ (i.e. a
fixed list of disorders): having NIPT means having the fetus
tested for all disorders included in the offer; (2) ‘optional
packages’: the offer of disorders is divided into categories,
containing disorders similar in type and severity; the woman
Figure 1 Preference of health professionals concerning the position of noninvasive prenatal testing in the prenatal screening program. Totals
may not add up to 100% because of missing values and rounding. FCT = first-trimester combined test, NT = nuchal translucency,
MSS =maternal serum screening. *Other included the following: NIPT with FCT (n = 3), NIPT with 12-weeks ultrasound (n = 2), and I don’t
know yet (n = 2)
Table 2 Attitudes of health professionals toward replacement of first-trimester combined test by noninvasive prenatal test and
considerations for counseling







…has only advantages 74 (32) 26 (11) 135 (57)
…will simplify the counseling 91 (39) 35 (15) 110 (47)
…will lead to more pregnant women deciding to do the test 30 (13) 43 (18) 163 (69)
…will lead to pregnant women agreeing with screening without fully thinking
through this decision
65 (28) 54 (23) 115 (49)
When counseling for NIPT in comparison to counseling for FCT…
…the procedure of the test is easier to explain 46 (20) 39 (17) 151 (64)
…there is more time to give information about the disorders that will be tested 70 (30) 74 (31) 92 (39)
…it is unnecessary to give an explanation about invasive testing because only a few
pregnant women will need this follow-up test
199 (84) 15 (6) 22 (9)
… less time for consideration can be given to pregnant women to do the test or not 175 (74) 38 (16) 23 (10)
…the counseling and procedure of the test (sampling of maternal blood) can
take place the same day
140 (59) 36 (15) 60 (25)
Totals may not add up to 100% because of missing values and rounding.
FCT, first-trimester combined test; NIPT, noninvasive prenatal test.
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can choose for which category or categories she wants to have
testing; and (3) ‘free choice’: the woman can choose herself
which disorders in the offer the fetus is and is not tested for
(i.e. choice from a list of disorders). The final section included
demographic questions about age, gender, profession, years
in profession, and work region.
Data analysis
Descriptive analyses were used to describe the characteristics
of the respondents. The 5-point Likert scale used to measure
agreement on the attitudes statements was compressed into
a 3-point scale in order to avoid small cell sizes: (1) completely
disagree or disagree; (2) neither disagree nor agree; and (3)
agree or completely agree. Multinomial logistic regression
analyses were used to investigate differences between
attitudes of health professionals with different professional
backgrounds from Amsterdam and Groningen on the position
of NIPT in the prenatal screening program. Those attitudes
included the following subjects: (1) the position of NIPT in
the prenatal screening program, (2) the potential replacement
of FCT by NIPT and possible consequences for counseling,
and (3) the range of disorders for which NIPT should be made
available and how to offer NIPT for a broader range of
disorders. Ordinal logistic regression analyses were used
to rank the information about NIPT that would be the
most important for pregnant women according to health
professionals. All analyses were adjusted for age and years of
experience. Gender could not be included in the analyses as
only 12 males participated. To account for multiple testing, a
p-value of <0.01 was used to indicate statistical significance.
A Chi-squared test was used to compare the attitudes of
health professionals and pregnant women. Statistical analysis
was performed using SPSS20.0 (IBM Statistics for Windows,
IBM, NY, USA). When significant differences between the
responses of health professionals based upon different




In total, 200 surveys were distributed in Amsterdam and 300 in
Groningen. Because these are estimated values, and online
participation was allowed, it was not possible to measure an
exact response rate. A total of 241 health professionals returned
the questionnaire (Table 1). One respondent who did not fully
complete the questionnaire was excluded from the analysis,
resulting in an inclusion of 240 respondents. The mean age
was 40.2 years (SD 11.1, range 20–65 years). The majority were
female (94%), and more than half of the respondents were
midwives (58%). The mean years of working experience was
12.9 (SD 10.6, range 0–55 years). Themajority of the respondents
worked in the region of Amsterdam (63%, n = 151). The majority
of the Northern respondents were midwives (75%) compared
with 48% midwives in the Western region.
Positioning NIPT in the prenatal screening program
Most respondents (72%, n = 171) thought that NIPT should
replace FCT, but 43% (n = 102) preferred maintenance of NT
measurement (Figure 1). A minority (22%, n = 53) thought that
FCT should be maintained and NIPT should be offered as a
follow-up test after a high risk at FCT. The probability of being
in favor of full replacement of FCT by NIPT versus NIPT while
preserving NT was significantly lower for sonographers (9% vs
48%) than for midwives (34% vs 42%) (OR= 0.181, p = 0.010).
Attitudes on replacement of FCT by NIPT
Many respondents (57%) thought that replacement of FCT by
NIPT only has advantages, would make explaining test
procedures easier (64%), and would simplify counseling (47%)
(Table 2). Most health professionals (69%) believed that NIPT
would lead to more pregnant women deciding to choose
prenatal testing, and almost half (49%) believed that this would
lead to pregnant women agreeing with screening without fully
thinking through this decision. The majority (84%) disagreed
with the statement that it would be unnecessary to give an
Figure 2 Ranking of important features of noninvasive prenatal testing for pregnant women according to health professionals (mean values,
1 =most important, 6 = least important)
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explanation about invasive testing because few pregnant
women would need follow-up testing. Moreover, 74% of
respondents disagreed that pregnant women should be given
less time to decide for or against testing, and only 25% believed
that counseling for NIPT and sampling of maternal blood
should take place on the same day. Significantly more
gynecologists (46%, n = 20/44) (OR = 0.155, p = 0.000) and
sonographers (37%, n = 16/43) (OR = 0.220, p = 0.001) compared
with midwives (15%, n = 21/138) favored this last statement.
Health professionals were asked to indicate what
information about NIPT would be the most important
according to pregnant women (Figure 2). Accuracy (1.64,
SD 0.79) followed by safety (2.03, SD 1.1) of the test were
considered to be the most important. The least important
was costs (4.62, SD 1.2) and information about test procedure
(4.74, SD 1.3).
Offering NIPT for a broader potential: ‘what to offer’ and ‘how
to offer’?
The attitudes of health professionals toward NIPT-based
screening for a broader range of disorders are shown in Figure 3.
The majority thought that NIPT should be used for disorders
characterized by neonatal death or death within the first year
of life (92%) or disorders for which children would need medical
care throughout their lives (71%). A little more than half of the
respondents (52%) agreed that screening for fetomaternal risk
factors that have a negative influence on pregnancy outcome
should be offered.
The attitudes of health professionals from our study versus
those of pregnant women (based on the results of the study
of Van Schendel et al29) are shown in Figure 4. Overall, 46%
(n = 111) of the health professionals thought that if NIPT-based
screening is introduced for a broader range of disorders,
this should be made available as a closed offer (i.e. fixed list
of disorders), which was significantly less preferred by
pregnant women (31%, n = 118/381) (p< 0.001). Fewer health
professionals (25%, n = 61) believed that pregnant women
should have a free choice, compared with pregnant women
(41%, n = 157/381) (p< 0.001).
DISCUSSION
Positioning NIPT in the prenatal screening program
This study shows that the majority (72%) of Dutch obstetric
health professionals are in favor of replacing FCT by NIPT,
which is in line with previous reported studies among obstetric
health providers from the USA.14,15 However, 43% of the
respondents in our study do state that when replacing FCT,
NT measurement should be preserved. This corresponds with
a survey among 278 US maternal fetal-medicine specialists
concerning the clinical implementation of NIPT, where 71%
of the respondents did not agree with NIPT replacing NT
measurement.30 Only a minority of the sonographers in our
study preferred a full replacement of FCT by NIPT. It may be
that because of their daily practice they see an additional value
in a first-trimester scan, including NT measurement. There are
concerns that important information about fetal conditions or
fetomaternal risk factors (other than trisomy 21, 13, or 18)
currently detected by an ultrasound scan at 12 to 13 weeks will
be overlooked.2,13 However, regarding other chromosomal
anomalies, a recent retrospective cohort study suggested that
only very few fetuses with a chromosomal abnormality other
than trisomy 21, 13, or 18 would have been missed when using
NIPT instead of FCT.31 An approach could be to perform an
ultrasound scan at 12 to 13 weeks with NT measurement
alongside NIPT, or alternatively postponing NIPT after this
scan, although evidence on its clinical utility is still under
investigation.12,13 This last option would save costs in the case
of intra-uterine demise occurring early in pregnancy and select
fetuses with very enlarged NT, eligible for a broader genetic
work-up than NIPT.32 Still, as first-trimester screening in the
Netherlands aims exclusively to detect trisomy 21, 18, or 13,
broadening the scope of screening should be preceded by a
redefinition of the screening target.33
Figure 3 Opinion of health professionals toward noninvasive prenatal testing for a broader range of disorders. *Other included the following:
disorders for which the parents wish to do testing (n = 3), not expanding the scope (n = 2), only in the case of a familiar disease (n = 2), and
severe disorders (n = 2)
S. Tamminga et al.1320
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Attitudes toward replacement of FCT by NIPT
Most respondents in our study believed that NIPT is an easier
test to explain, which will simplify counseling. Although, half
of the health professionals in this study stated that pregnant
women might agree with screening without fully thinking about
this decision. In addition, the majority of the respondents
disagreed that counseling and sampling of maternal blood
should take place on the same day. These results may illustrate
possible concerns that the assumed benefits of NIPT, such as
rapid, simple, and efficient testing, could threaten informed
decision-making. These possible concerns should be taken
seriously when NIPT is considered as a first-tier screening test.
It is known that separating the test offer from the test procedure
gives time for reflection, yet there is no empirical evidence that
counseling and testing the same day will necessarily lead to an
uninformed decision to accept the test.17 A way to optimize
autonomous reproductive choice may be to make use of
(online) decision aids prior to pre-test counseling for NIPT. A
randomized controlled trial among 701 US pregnant women
showed that an interactive decision-support guide about
prenatal testing resulted in more informed choices.34
In the Netherlands, counseling high-risk pregnant women
about NIPT is currently performed by trained health
professionals (mainly gynecologists) in the eight University
Medical Centers. If NIPT were to be offered to all pregnant
women, this would shift pre-test counseling to mainly primary
care midwives who, up till now, have limited clinical
experience with NIPT. Educational programs as well as proper
guidelines for professionals are needed to maintain a high
standard of care and to ensure that couples are able to make
a well-informed decision. While it has already been shown that
health professionals themselves consider accuracy of the test
to be the most important feature of a prenatal test,18–20 this
study showed that health professionals believe that pregnant
women share this opinion, while in fact pregnant women place
most value on the safety of a test.18–20
Attitudes toward offering NIPT for a broader scope
As to previously published data,14,20,23 the majority of health
professionals in our study were in favor of offering NIPT for
severe genetic disorders. Surprisingly, only a little over half of
the health professionals (52%) favored testing for fetomaternal
risk factors, which can have a negative effect on the course of
pregnancy, such as preeclampsia or preterm birth. The
questionnaire study of van Schendel et al.29 among 381
pregnant women showed that 65% of the respondents were in
favor of offering NIPT for these risk factors. It remains unclear
why Dutch health professionals and pregnant women are not
quite convinced to screen for these risk factors. Perhaps, health
professionals think that NIPT is not valid for predicting
outcome, such as for preeclampsia, or they find the efficacy of
therapies for risk factors during pregnancy debatable.
A minority of respondents of our study supported the use of
NIPT for adult-onset disorders or disorders for which children
will need little medical care throughout their lives. This would
rarely lead to termination of pregnancy, making the infor-
mational interests of the future child a topic to consider. In this
connection, it has been argued that the future child has a ‘right
to an open future’, including the right to decide later in life
whether ‘to know’ or ‘not to know’.13 Only 25% of health
professionals in our study favored offering NIPT as a free
choice from a list of disorders when broadening the scope of
NIPT. The previously mentioned study among Dutch pregnant
women showed that the largest group (41%) preferred to have
a free choice.29 Health professionals might raise objections to
this because of practical considerations, as counseling would
become a complicated and time-consuming task.24 The
discrepancy in attitudes may also reflect different views about
how the aim of enabling reproductive choice can best be
served.24 Whereas on the one hand, one might argue that an
individualized choice requires providing prospective parents
with the option to be informed about whatever they want to
know about the health of the future child, it has also been
Figure 4 Attitudes of health care professionals (n = 240) and pregnant women (n = 381) toward how to offer NIPT for a broader range
of disorders. *‘Other’ included for health professionals: I don’t know (yet) (n = 6), not expanding the scope of NIPT (n = 5), only for very
severe diseases (n = 3), and only for familial disorders (n = (2). ‘Other’ for pregnant women included a medical doctor or board decides which
diseases to offer (n = 3), only for familial disorders (n = 2)
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pointed out that an unlimited choice will lead to information
overload, which may paradoxically undermine reproductive
autonomy rather than serve it.35 Many women are, in
principle, in favor of ‘having a free choice’, but also
acknowledge that the decision-making process might become
complex and possibly overburden pregnant women.24
Strengths and limitations
One of the strengths of this study is the relatively large sample
size and the different professional backgrounds represented.
No information on non-respondents has been collected, and
the study may have attracted more respondents that were
interested in NIPT. Also, this study only observed the opinion
of health professionals in the West and North of the
Netherlands and cannot be generalized to other professionals
in the Netherlands. In comparison to other countries, there is
a relatively low uptake of prenatal screening in the
Netherlands. Therefore, the interpretation of the results must
be performed with caution, as these might not be generalizable
to countries with a higher uptake. Noteworthy, this survey
study was performed before, and for some right at the time
NIPT was first introduced in the Netherlands. The attitudes of
the majority of health professionals were thus based only on
information about NIPT rather than on their own clinical
experience with the test.
CONCLUSION
Dutch health professionals have a positive attitude toward
offering NIPT as a first-tier screening test to all pregnant
women. The additional value of NT measurement if NIPT fully
replaces FCT needs to be further investigated, as many
professionals preferred to preserve the NT measurement. If
NIPT was to be offered as a first-tier screening test, this would
lead to a significant change in the organization of the
counseling in the Netherlands, as it would then be primarily
performed by primary care midwives. Most respondents in
our study believe that NIPT is an easier test to explain, thereby
simplifying counseling. Attention should be paid to ensure that
patients make well-informed decisions, especially in the light
of concerns about a possible routinization effect that would
be at odds with the aim of prenatal screening. The prospect
that, in the future, NIPT might be used for a broader range of
disorders makes it imperative to consider how prenatal
screening should then be offered and for which conditions.
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WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• Noninvasive prenatal testing (NIPT) for aneuploidy screening has
high accuracy regardless of pregnant women’s risk.
• Maternal plasma contains the entire fetal genome, potentially
widening the scope of NIPT.
WHAT DOES THIS STUDY ADD?
• Health professionals favor offering NIPT to all women; most want to
maintain nuchal fold measurement.
• The majority (92%) of health professionals thought NIPT-based
screening should include disorders characterized by neonatal death
or death within the first year of life; 52% favored testing for
fetomaternal risk factors.
• Most health professionals thought that a broader range of disorders
should be offered as a ‘fixed list of disorders’ in contrast to pregnant
women who mostly preferred to have a free choice.
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